Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $10.60 Analyst target: $41.49 Upside: 291.60%
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company is headquartered in Toronto, Canada.
See the full interactive analysis & chart →Informational only — not investment advice.